Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

October 5, 2015

Primary Completion Date

October 24, 2019

Study Completion Date

October 24, 2019

Conditions
Hodgkin LymphomaNon-Hodgkin Lymphoma
Interventions
DRUG

Camidanlumab tesirine

Intravenous (IV) infusion.

Trial Locations (12)

10065

Memorial Sloan-Kettering Cancer Center, New York

22031

Virginia Cancer Specialists, PC, Fairfax

44106

University Hospitals Cleveland Medical Center, Cleveland

53226

Froedtert Hospital/Medical College of Wisconsin, Milwaukee

78229

Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio

91010

City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte

77030-4009

The University of Texas/MD Anderson Cancer Center, Houston

SE1 9RT

Guy's and St. Thomas' Hospital NHS Trust, London

Unknown

The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne

Southampton General Hospital, University Hospital Southampton NHS Foundation Trust, Southampton

OX3 7LE

Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford

M20 4BX

The Christie NHS Foundation Trust, Manchester

Sponsors
All Listed Sponsors
lead

ADC Therapeutics S.A.

INDUSTRY